Wetzel E, Müller-Quernheim J, Lorenz J
Krankenanstalt, Mutterhaus der Borromäerinnen Trier, Akademisches Lehrkrankenhaus, Universität Mainz.
Pneumologie. 1999 Jul;53(7):323-8.
Adenosin deaminase (ADA) is an enzyme of purine metabolism and reflects the involvement of the cellular immune system. The ADA serum levels were tested in 130 healthy blood donors, and in 98 patients (pts) with sarcoidosis; 59 pts with active and 39 pts with inactive sarcoidosis. These two patient groups were separated into treated and untreated; the active group was divided into an acute onset group (12 pts) and a group with chronic disease (47 pts). The disease activity was determined on the basis of clinical symptoms, chest x-ray and lung function tests. ADA was compared to angiotensin converting enzyme(ACE), neopterin (NPT), and soluble interleukin-2 receptor (sIL-2 R). ADA activity was measured colorimetrically according to a method of Giusti with slight modifications. ACE was determined by a commercial kit by Fujerbio, Japan. NPT and sIL-2 R were evaluated by commercial enzyme-linked immunosorbent assays. The ADA activity in controls was 18.8 +/- 3.8 U/I (mean +/- SD), the upper normal serum range (mean +/- 2SD) was established at 26.4 U/I. Serum ADA levels in the group with active sarcoidosis (33.5 +/- 14.3 U/I, p < 0.0001) were significantly higher than those in healthy controls and in inactive disease (19.6 +/- 5.8 U/I, p < 0.0001). Sensitivity and specificity were: ADA 75%/92%, ACE 49%/85%, NPT 78%/74%, sIL-2 R 81%/57%.
Our findings demonstrate that the course of the disease can be monitored by measurement of the serum ADA. In comparison to the other parameters, measurement of the serum ADA indicates a greater discrimination between active and inactive disease.
腺苷脱氨酶(ADA)是嘌呤代谢中的一种酶,反映细胞免疫系统的参与情况。对130名健康献血者以及98例结节病患者进行了ADA血清水平检测;其中59例为活动期结节病患者,39例为非活动期结节病患者。这两组患者又分为治疗组和未治疗组;活动期组分为急性起病组(12例)和慢性病组(47例)。根据临床症状、胸部X线和肺功能检查确定疾病活动度。将ADA与血管紧张素转换酶(ACE)、新蝶呤(NPT)和可溶性白细胞介素-2受体(sIL-2R)进行比较。ADA活性采用Giusti方法并略作修改,通过比色法测定。ACE由日本Fujerbio的商用试剂盒测定。NPT和sIL-2R通过商用酶联免疫吸附测定法评估。对照组的ADA活性为18.8±3.8U/I(平均值±标准差),正常血清上限范围(平均值±2标准差)设定为26.4U/I。活动期结节病组的血清ADA水平(33.5±14.3U/I,p<0.0001)显著高于健康对照组和非活动期疾病组(19.6±5.8U/I,p<0.0001)。敏感性和特异性分别为:ADA 75%/92%,ACE 49%/85%,NPT 78%/74%,sIL-2R 81%/57%。
我们的研究结果表明,通过测定血清ADA可以监测疾病进程。与其他参数相比,血清ADA的测定显示出活动期和非活动期疾病之间更大的区分度。